Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Oxymetazoline for Facial Erythema in Rosacea
NCT03352323Phase 3Completed
- Sponsor
- Padagis
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of oxymetazoline in rosacea, sponsored by Padagis. Primary endpoint: Responder at 15 days. Started Oct 2017; status: completed.
02
Drugs
oxymetazoline
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT03352323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03352323.